GlassScriptPhysician profile
Aimalohi Gray
NPI 1750949640
$1,960.09
in general payments reported to CMS, 2019-2025
24 companies · $895 in 2025
The $895 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $239 · 2023: $520 · 2024: $306 · 2025: $895.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,721.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,721.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $278.16 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $275.69 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $233.17 | 2023-2025 | |
| Lilly USA, LLC | $164.69 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $138.50 | 2023-2025 | Otezla, Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $129.38 | 2022-2025 | Jardiance, Tradjenta |
| Glaxosmithkline, LLC. | $119.50 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $98.94 | 2023-2025 | Xifaxan |
| Pfizer INC. | $80.08 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $66.74 | 2023-2024 | Rexulti |
| Seqirus USA INC | $54.14 | 2025 | Flucelvax, Fluad |
| Abbott Laboratories | $37.19 | 2025 | Freestyle Libre 3 |
| Lundbeck LLC | $33.24 | 2023-2024 | Rexulti |
| Ucb, INC. | $32.15 | 2023 | Nayzilam |
| Renalytix Ai, INC. | $32.13 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $27.75 | 2025 | |
| Astellas Pharma US INC | $25.41 | 2025 | Veozah |
| Collegium Pharmaceutical, INC. | $24.24 | 2023 | Belbuca |
| Shield Therapeutics INC | $23.27 | 2024 | |
| Sanofi-Aventis U.S. LLC | $21.23 | 2022 | |
| Gilead Sciences, INC. | $16.94 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $16.78 | 2022 | |
| Janssen Pharmaceuticals, INC | $16.27 | 2023 | Spravato |
| Exact Sciences Corporation | $14.50 | 2024 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aimalohi Gray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.